EE9900039A - Paratüreoidhormooni analoogid osteoporoosi raviks - Google Patents
Paratüreoidhormooni analoogid osteoporoosi raviksInfo
- Publication number
- EE9900039A EE9900039A EEP199900039A EE9900039A EE9900039A EE 9900039 A EE9900039 A EE 9900039A EE P199900039 A EEP199900039 A EE P199900039A EE 9900039 A EE9900039 A EE 9900039A EE 9900039 A EE9900039 A EE 9900039A
- Authority
- EE
- Estonia
- Prior art keywords
- analogues
- lys
- activities
- parathyroid hormone
- rat
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title 1
- 102000003982 Parathyroid hormone Human genes 0.000 title 1
- 108090000445 Parathyroid hormone Proteins 0.000 title 1
- 239000000199 parathyroid hormone Substances 0.000 title 1
- 229960001319 parathyroid hormone Drugs 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 3
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 230000001077 hypotensive effect Effects 0.000 abstract 2
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 abstract 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 abstract 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 abstract 1
- 102000030621 adenylate cyclase Human genes 0.000 abstract 1
- 108060000200 adenylate cyclase Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 102000058004 human PTH Human genes 0.000 abstract 1
- 125000001165 hydrophobic group Chemical group 0.000 abstract 1
- 150000003951 lactams Chemical class 0.000 abstract 1
- 230000002188 osteogenic effect Effects 0.000 abstract 1
- 201000008968 osteosarcoma Diseases 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000011552 rat model Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measurement Of Radiation (AREA)
- Display Devices Of Pinball Game Machines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/691,647 US5955425A (en) | 1996-08-02 | 1996-08-02 | Parathyroid hormone analogues for the treatment of osteoporosis |
| US4056097P | 1997-03-14 | 1997-03-14 | |
| PCT/CA1997/000547 WO1998005683A1 (en) | 1996-08-02 | 1997-08-01 | Parathyroid hormone analogues for the treatment of osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE9900039A true EE9900039A (et) | 1999-08-16 |
Family
ID=26717175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP199900039A EE9900039A (et) | 1996-08-02 | 1997-08-01 | Paratüreoidhormooni analoogid osteoporoosi raviks |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP0915911B1 (et) |
| JP (3) | JP4122061B2 (et) |
| KR (1) | KR100500859B1 (et) |
| CN (1) | CN1176947C (et) |
| AT (1) | ATE253078T1 (et) |
| AU (1) | AU723728B2 (et) |
| BG (1) | BG103128A (et) |
| BR (1) | BR9711002B1 (et) |
| CA (1) | CA2261564C (et) |
| CZ (1) | CZ34799A3 (et) |
| DE (1) | DE69725850T2 (et) |
| DK (1) | DK0915911T3 (et) |
| EE (1) | EE9900039A (et) |
| ES (1) | ES2207740T3 (et) |
| FI (1) | FI990126A (et) |
| GE (1) | GEP20033095B (et) |
| IS (1) | IS4962A (et) |
| LV (1) | LV12293B (et) |
| NZ (1) | NZ333809A (et) |
| PT (1) | PT915911E (et) |
| RU (1) | RU2203286C2 (et) |
| SI (1) | SI9720057A (et) |
| SK (1) | SK287397B6 (et) |
| WO (1) | WO1998005683A1 (et) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL336803A1 (en) * | 1997-05-14 | 2000-07-17 | Rhone Poulenc Rorer Pharma | Analogues of peptidic parathyroid hormone |
| AU1447600A (en) | 1998-10-22 | 2000-05-08 | Thomas J. Gardella | Bioactive peptides and peptide derivatives of parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp) |
| JP4486258B2 (ja) | 1998-11-25 | 2010-06-23 | ザ・ジェネラル・ホスピタル・コーポレイション | ヒト副甲状腺ホルモンの改変、調製および使用 |
| WO2000040698A1 (en) | 1998-12-31 | 2000-07-13 | The General Hospital Corporation | Pth receptor and screening assay utilizing the same |
| AU777634B2 (en) * | 1999-07-28 | 2004-10-28 | Kazuhiro Aoki | Methods of inhibiting osteoclastogenesis |
| US6316410B1 (en) | 1999-09-22 | 2001-11-13 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
| EP1439854B1 (en) | 2001-07-23 | 2016-12-14 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
| WO2003059291A2 (en) | 2002-01-10 | 2003-07-24 | Osteotrophin Llc | Treatment of bone disorders with skeletal anabolic drugs |
| WO2004060386A1 (en) * | 2002-11-01 | 2004-07-22 | Amgen, Inc. | Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein |
| US8088734B2 (en) * | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
| EP1933863A4 (en) * | 2005-09-06 | 2010-06-09 | Zelos Therapeutics Inc | PARATHYROIDIAN HORMONE ANALOGS AND METHODS USING SAME |
| WO2008016404A2 (en) * | 2006-07-31 | 2008-02-07 | Zelos Therapeutics, Inc. | Parathyroid hormone analogues and uses thereof |
| CN101522709B (zh) | 2006-10-13 | 2013-03-20 | 伊莱利利公司 | 作为pth受体调节剂的聚乙二醇化的pth及其用途 |
| MX353986B (es) | 2007-08-01 | 2017-11-06 | Massachusetts Gen Hospital | Metodos de analisis y seleccion usando receptores acoplados a proteina g y composiciones relacionadas. |
| WO2011143406A2 (en) * | 2010-05-13 | 2011-11-17 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
| CN105440126B (zh) * | 2015-12-31 | 2019-10-25 | 南京工业大学 | 治疗骨质疏松的α-螺旋多肽及其制备方法与应用 |
| WO2019018238A1 (en) | 2017-07-15 | 2019-01-24 | The Regents Of The University Of California | CATHEPSIN K OSTEOADSORBENT FLUOROGEN SUBSTRATE FOR THE IMAGING OF OSTEOCLAST ACTIVITY AND MIGRATION |
| BR112021003442A2 (pt) | 2018-09-26 | 2021-05-18 | Borealis Ag | composição de copolímero de propileno com excelentes propriedades mecânicas e ópticas |
| JP7342310B2 (ja) | 2019-05-28 | 2023-09-12 | 国立大学法人東北大学 | 電源装置、超伝導装置、超伝導デバイス、及び超伝導デバイスの製造方法 |
| CN113549144A (zh) * | 2021-06-30 | 2021-10-26 | 华南理工大学 | 一种特立帕肽hPTH(1-34)的生产和纯化方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5317010A (en) * | 1991-10-10 | 1994-05-31 | Peter K. T. Pang | Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment |
| US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
| AU672790B2 (en) * | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
| CA2126299C (en) * | 1994-06-20 | 2000-12-12 | Gordon E. Willick | Parathyroid hormone analogues for the treatment of osteoporosis |
-
1997
- 1997-08-01 CZ CZ99347A patent/CZ34799A3/cs unknown
- 1997-08-01 SK SK132-99A patent/SK287397B6/sk not_active IP Right Cessation
- 1997-08-01 DK DK97933603T patent/DK0915911T3/da active
- 1997-08-01 CA CA002261564A patent/CA2261564C/en not_active Expired - Fee Related
- 1997-08-01 RU RU99104132/14A patent/RU2203286C2/ru not_active IP Right Cessation
- 1997-08-01 AT AT97933603T patent/ATE253078T1/de active
- 1997-08-01 CN CNB971981612A patent/CN1176947C/zh not_active Expired - Fee Related
- 1997-08-01 AU AU36905/97A patent/AU723728B2/en not_active Ceased
- 1997-08-01 EP EP97933603A patent/EP0915911B1/en not_active Expired - Lifetime
- 1997-08-01 SI SI9720057A patent/SI9720057A/sl not_active IP Right Cessation
- 1997-08-01 ES ES97933603T patent/ES2207740T3/es not_active Expired - Lifetime
- 1997-08-01 EE EEP199900039A patent/EE9900039A/et unknown
- 1997-08-01 DE DE69725850T patent/DE69725850T2/de not_active Expired - Lifetime
- 1997-08-01 WO PCT/CA1997/000547 patent/WO1998005683A1/en active IP Right Grant
- 1997-08-01 KR KR10-1999-7000903A patent/KR100500859B1/ko not_active IP Right Cessation
- 1997-08-01 BR BRPI9711002-7A patent/BR9711002B1/pt not_active IP Right Cessation
- 1997-08-01 NZ NZ333809A patent/NZ333809A/xx not_active IP Right Cessation
- 1997-08-01 JP JP50741398A patent/JP4122061B2/ja not_active Expired - Fee Related
- 1997-08-01 PT PT97933603T patent/PT915911E/pt unknown
- 1997-08-01 GE GEAP19974655A patent/GEP20033095B/en unknown
-
1999
- 1999-01-22 FI FI990126A patent/FI990126A/fi unknown
- 1999-01-28 BG BG103128A patent/BG103128A/xx unknown
- 1999-01-29 IS IS4962A patent/IS4962A/is unknown
- 1999-02-01 LV LVP-99-15A patent/LV12293B/en unknown
-
2007
- 2007-05-01 JP JP2007121289A patent/JP4224111B2/ja not_active Expired - Fee Related
-
2008
- 2008-09-25 JP JP2008246839A patent/JP2009057386A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE9900039A (et) | Paratüreoidhormooni analoogid osteoporoosi raviks | |
| WO2001021643A3 (en) | Parathyroid hormone analogues for the treatment of osteoporosis | |
| Chartrel et al. | Characterization of melanotropin-release-inhibiting factor (melanostatin) from frog brain: homology with human neuropeptide Y. | |
| DK0946191T3 (da) | Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme | |
| NZ502872A (en) | Mevinolin and compaction as LFA-1 antagonists for treating autoimmune diseases | |
| AP2000001888A0 (en) | Method for treatment of diabetes using peptides analogues of insulin. | |
| AU5567790A (en) | Device for reinforcing and sustaining the cap of the rotators of a human shoulder joint | |
| HUP0004560A2 (hu) | Törést gyógyító PTHrP analógok | |
| MY137457A (en) | Cyclic peptides having melanocortin-4 receptor agonist activity | |
| RU99104132A (ru) | Аналоги паратиреоидного гормона для лечения остеопороза | |
| ATE377026T1 (de) | Behandlung von fettleibigkeit | |
| ATE279440T1 (de) | Wachstumshormonsekretionsförderer rezeptorfamilie | |
| EP0182627A3 (en) | Basic v1-vasopressin antagonists | |
| NO975565L (no) | Benstimulerende faktor | |
| ITMI912582A1 (it) | Mutanti dell'ormone della crescita umano e loro impiego | |
| EP0182626A3 (en) | V1-vasopressin antagonists | |
| DE69901690T2 (de) | Verwendung von vip analoge für vorbeugung und behandlung von gehirnbeschädigungen von menschlichen neugeborenen | |
| ATE178073T1 (de) | Superaktive analoga des wachstumshormon- releasingfaktors | |
| ATE412669T1 (de) | Calicitonin-analoga mit stark erhöhter hypocalcämischer wirkung in vivo | |
| DK119391A (da) | Humaninsulinanaloger |